Email this pageOxcarbazepine XR Double Blind Study for Partial Seizures
| Purpose | Supernus is conducting this study to study the safety and the effects of two different doses of Oxcarbazepine XR (1200mg/day and 2400mg/day) given as adjunctive therapy for the treatment of seizures that occur in one area of the brain in subjects with epilepsy that is difficult to treat with medication. | |||
|---|---|---|---|---|
| Details | Study Number 20082235 |
Accepts Adults? Yes |
Accepts Children? No |
Fully Enrolled? No |
| Contacts | Principal Investigator A. James Fessler III, M.D. |
Contact Diane Smith, (585)275-0404 |
||
For More Information
Please call the phone number listed above and the clinical trial coordinator will contact you.
